The treatment for breast and prostate cancer are under intense progress.
Cancer of the prostate is the second most frequently diagnosed cancer in men
in the US and approximately 3 million women in the US are living with breast
cancer. Several new approvals have changed the landscape of options for the
treatment of late stage breast and prostate cancer. Newly approved drugs are
showing increased sale figures, and several of them are reaching for broader
indications. So, the trend of continuously increasing revenues is expected for
drugs presenting reliable clinical data to support their successful progress.
Research and analysis highlights
In the report "Prostate & Breast Cancer - New Treatments & Developmental
Progress" BioSeeker does not only describe and analyze the latest years of
progress but as well provide an insight and framework to understand the
complex field of prostate & breast cancer therapeutics. In this report, we
provide one of the most comprehensive coverage of the R&D trends to set the
future marketplace. BioSeeker presents both an overview and a detailed
description on the progress of key drugs in Phase III and II development,
together with general descriptions on drugs and targets. We have identified
approximately 200 drug candidates in clinical stage of development and more
than 125 companies are involved in the development of these drugs. Among these
drugs we clearly see substantial progress while others have failed. There will
be a more intense competition in these markets and current treatments will be
changed for the benefit of more innovative therapies.
Scope of this report
Thorough examination of status and impact of several novel drugs in
development
Discussion of the challenges in current and future treatment strategies
Anticancer pipeline of most companies in the field
Key reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical
development. Scientific rationale for most novel therapeutics in breast and
prostate cancer R&D, and the results of clinical trials to date
Gain insight into the current challenges and commercial opportunities
associated with breast and prostate cancer therapy
Two hundred high quality references
Table of Contents
1 Executive Summary
2 Methodology
3 Table of Contents
3.1 List of Boxes
3.2 List of Tables
4 Prostate Cancer
4.1.1 Introduction
4.1.2 Disease Definitions
4.1.3 Etiology & Pathophysiology
4.1.4 Epidemiology
4.1.5 Prognosis
4.2 Current Treatment Strategies
4.2.1 Localized Disease
4.2.1.1 Locally Advanced Prostate Cancer
4.2.2 Metastatic Prostate Cancer
4.2.2.1 Hormone-Sensitive Metastatic Prostate Cancer
4.2.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
4.3 Progress in Current Treatment Strategies
4.3.1 Hormone Modulators
4.3.2 Chemotherapy
4.4 Key Therapeutic Strategies for Future Therapies
4.4.1 Therapeutic Type, Targets & Mechanisms
4.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
4.5.1 Hormone Modulators
4.5.2 Protein Kinase Inhibitors
4.5.3 Apoptotic Inducers
4.5.4 Immunotherapy
4.5.5 DNA Binding
4.5.6 Other
4.6 Current Drug Development: The Early Stage Pipeline
4.6.1 Epothilones
4.6.2 Protein Kinse Inhibitors
4.6.3 Other
4.6.4 Chemotherapy
5 Breast Cancer
5.1 Introduction
5.1.1 Disease Definitions
5.1.2 Etiology
5.1.3 Epidemiology
5.1.4 Prognosis
5.2 Current Treatment Strategies
5.2.1 Localized Disease
5.2.2 Advanced Disease
5.3 Progress in Current Treatment Strategies
5.3.1 Hormone Based Therapies
5.3.2 Antibodies
5.3.3 Chemotherapy
5.4 Key Therapeutic Strategies for Future Therapies
5.4.1 Therapeutic Type, Targets & Mechanisms
5.5 Competitive Landscape in Drug Development: The Late Stage Pipeline
5.5.1 The Epothilones
5.5.2 Cell Cycle & Apoptosis
5.5.3 Protein Kinase Inhibitors
5.5.4 Immunotherapy
5.6 Current Drug Development: The Early Stage Pipeline
5.6.1 DNA Targeting
5.6.2 FTIs
5.6.3 Antisense
5.6.4 New Hormone Modulators
5.6.5 Other
5.7 Disclaimer
5.7.1 Liability
5.7.2 Completeness
6 Drug Index
7 Company Index
List of Boxes
Box 1: The Eastern Cooperative Oncology Group Study
Box 2: Southwest Oncology Group Study 99-16 Design
Box 3: TAX 327 Study Design
Box 4: Quick Facts - Toremifene
Box 5: Quick Facts - Bevacizumab
Box 6: Quick Facts - Genasense
Box 7: Quick Facts - R-flurbiprofen
Box 8: Quick Facts - Exisulind
Box 9: Quick Facts - Provenge
Box 10: Quick Facts - GVAX
Box 11: Quick Facts - Satraplatin
Box 12: Quick Facts - Vapreotide
Box 13: Quick Facts - DCVax
Box 14: Ongoing Phase III Studies Anastrozole
Box 15: Ongoing Phase III Studies Letrozole
Box 16: Ongoing Phase III Studies Exemestane
Box 17: Ongoing Phase III Studies Goserelin
Box 18: Ongoing Phase III Studies Fulvestrant
Box 19: Ongoing Phase III Studies Trastuzumab
Box 20: Quick Facts - BMS-247550
Box 21: Quick Facts - Temsirolimus
Box 22: Quick Facts - SDX-105
Box 23: Quick Facts - 4HPR
Box 24: Quick Facts - Lapatinib
Box 25: Quick Facts - Bevacizumab
Box 26: Quick Facts - Theratope
Box 27: Erlotinib
Box 28: Gefitinib
Box 29: Imatinib
Box 30: Pemetrexed
Box 31: NX473
Box 32: Lonafarnib
Box 33: Tipifarnib
Box 34: Bortezomib
Box 35: Arzoxifene
Box 36: Patupilone
Box 37: KOS-862
List of Tables
Table 1: The TNM System
Table 2: Lifestyle factors
Table 3: Historical Summary of Clinical Studies on Patients with Late
Stage Disease
Table 4: Short Facts Bicalutamide
Table 5: Short Facts Flutamide
Table 6: Short Facts Goserelin
Table 7: Short Facts Histrelin
Table 8: Short Facts Lanreotide
Table 9: Short Facts Leuprolide
Table 10: Short Facts Nilutamide
Table 11: Short Facts Abarelix
Table 12: Short Facts Mitoxantrone
Table 13: Short Facts Carboplatin
Table 14: Short Facts Docetaxel
Table 15: Short Facts Estramustine
Table 16: Summary of Recent Clinical Studies on Patients with Late Stage
Disease
Table 17: Ongoing Late Stage Clinical Studies
Table 18: Cancer Immunotherapy Strategies
Table 19: Near Term Progress Toremifene
Table 20: Near Term Progress Bevacizumab
Table 21: Near Term Progress Oblimersen
Table 22: Near Term Progress R-flurbiprofen
Table 23: Near Term Progress Exisulind
Table 24: Near Term Progress APC8015
Table 25: Near Term Progress GVAX
Table 26: Near Term Progress Satraplatin
Table 27: Summary of Prostate Cancer Late Stage Pipeline
Table 28: Epothilone
Table 29: Ixabepilone
Table 30: PTK/ZK
Table 31: Imatinib
Table 32: Bortezomib
Table 33: Sorafenib
Table 34: Arsenic trioxide
Table 35: Retinoic Acid
Table 36: Paclitaxel
Table 37: Doxorubicin
Table 38: Summary of Prostate Cancer Early Stage Pipeline
Table 39: The Stage System
Table 40: Risk Factors
Table 41: List of Approved Drugs and Their Mechanisms of Action.
Table 42: Hormonal Treatment Strategies
Table 43: Adjuvant Systemic Treatment Options for Women With Axillary
Node-Negative Breast Cancer
Table 44: Treatment Options for Women With Axillary Node-Positive Breast
Cancer
Table 45: Chemotherapy Drugs and Regimen
Table 46: Summay of Drugs Involved in Breast Cancer Therapy
Table 47: Short Facts Tamoxifen
Table 48: Short Facts Anastrozole
Table 49: Short Facts Letrozole
Table 50: Short Facts Exemestane
Table 51: Short Facts Goserelin
Table 52: Short Facts Fulvestrant
Table 53: Short Facts Trastuzumab
Table 54: Cancer Immunotherapy Strategies
Table 55: Progress on Ixabepilone
Table 56: Progress on CCI-779
Table 57: Progress on Fenretinide
Table 58: Progress on Lapatinib
Table 59: Progress on Bevacizumab
Table 60: Progress on Theratope
Table 61: Summary of Mid-Stage to Late stage Investigational Agents Under
Development
Table 62: Summary of Breast Cancer Early Stage Pipeline
※この商品は英文にてご提供いたします。
【 英文市場調査報告書 】
前立腺癌および乳癌：新たな治療法と開発動向
Prostate & Breast Cancer- New Treatments & Developmental Progres
出版日 : 2007/03
医薬品
その他のカテゴリ
FAQ